Download PDF
Neuropediatrics
DOI: 10.1055/a-2505-8310
Original Article

The Effect of Genotype Differences on Cardiac Involvement in Cases Diagnosed with Duchenne Muscular Dystrophy

Gizem Doğan 
1   Department of Pediatric Neurology, University of Health Sciences, Tepecik Training and Research Hospital, Izmir, Turkey
,
Gamze Sarıkaya Uzan 
1   Department of Pediatric Neurology, University of Health Sciences, Tepecik Training and Research Hospital, Izmir, Turkey
,
Yiğithan Güzin 
1   Department of Pediatric Neurology, University of Health Sciences, Tepecik Training and Research Hospital, Izmir, Turkey
,
Figen Baydan 
1   Department of Pediatric Neurology, University of Health Sciences, Tepecik Training and Research Hospital, Izmir, Turkey
,
Kayı Eliacık 
2   Department of Pediatric, University of Health Sciences, Tepecik Training and Research Hospital, Izmir, Turkey
,
Barıs Güven
3   Department of Pediatric Cardiology, University of Health Sciences, Tepecik Training and Research Hospital, Izmir, Turkey
,
Ali Rahmi Bakiler 
3   Department of Pediatric Cardiology, University of Health Sciences, Tepecik Training and Research Hospital, Izmir, Turkey
› Author Affiliations Funding None.
› Further Information
Also available at
    Permissions and Reprints

Abstract

Aim Duchenne muscular dystrophy (DMD) is the most frequently seen muscular disease in childhood. Cardiac involvement is extremely important in terms of morbidity and mortality in these patients. Different studies have shown that mutations occurring in various exons are cardioprotective or increase cardiac involvement in DMD cases. The aim of this study was to examine the effect of genotype differences on cardiac involvement in patients diagnosed with DMD with genetic analysis.

Material and Method A retrospective analysis of DMD patients followed up in the Muscle Diseases Centre of Health Sciences University Izmir Tepecik Training and Research Hospital was done.

Results Evaluation was made of 120 male DMD patients with a mean age of 9.66 ± 5.10 years. According to the genetic analysis results, 76.7% deletions, 15.8% mutations, and 7.5% duplications were determined. Of the mutations determined, 65.8% were between exons 44 and 54, 17.5% between exons 1 and 18, and 9.2% between exons 19 and 43, 5.8% were non-sense mutations, and 1.7% were on exons >54. In the cases determined with cardiac involvement, the mean age of onset was 11.87 ± 3.11 years. When ejection fraction (EF) <56% or fractional shortening (FS) <28% was accepted as systolic dysfunction cardiac effect, 12.5% of the cases were determined with cardiac involvement. Of the cases determined with cardiac effects, 86.7% were aged >10 years. Electrocardiography was evaluated as normal in 54.5%, sinus tachycardia in 24.2%, short PR in 15.2%, and right and left ventricle hypertrophy in 8.1%. No statistically significant difference was determined in mutation types and location according to the age of cardiac involvement. The left ventricle (LV) posterior wall thickness value determined in the exon 44–54 group was higher than in DMD cases with other mutations. Although not statistically significant, an important result was that the LV posterior wall and IVSed values were evaluated to be high.

Conclusion The current study results and findings in literature have not found a clear relationship between genotypes and cardiac involvement in DMD cases.

Keywords

Duchenne muscular dystrophy - genotype - heart failure - muscular dystrophies

Availability of Data and Material

The lead author* affirms that this manuscript is an honest, accurate, and transparent account of the study being reported, that no important aspects of the study have been omitted, and that any discrepancies in the study as planned (and, if relevant, registered) have been explained. * Guarantor of the manuscript.




Publication History

Received: 02 September 2024

Accepted: 14 December 2024

Article published online:
13 January 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 

  • References

  • 1 Heutinck L, Kampen NV, Jansen M, Groot IJ. Physical activity in boys with duchenne muscular dystrophy is lower and less demanding compared to healthy boys. J Child Neurol 2017; 32 (05) 450-457
    CrossrefPubMedSearch in Google Scholar
  • 2 Satman İ, Güdük Ö, Yemenici M, Ertürk N. Türkiye Halk Sağlığı ve Kronik Hastalıklar Enstitüsü, Nadir Hastalıklar Raporu, 2019; 23
  • 3 Topaloglu H. Duchenne muscular dystophy: a short review and treatment update. Iran J Child Neurol 2021; 15 (02) 9-15
    PubMedSearch in Google Scholar
  • 4 Aartsma-Rus A, Ginjaar IB, Bushby K. The importance of genetic diagnosis for Duchenne muscular dystrophy. J Med Genet 2016; 53 (03) 145-151
    CrossrefPubMedSearch in Google Scholar
  • 5 Sun C, Shen L, Zhang Z, Xie X. Therapeutic strategies for Duchenne muscular dystrophy: an update. Genes (Basel) 2020; 11 (08) 837
    CrossrefPubMedSearch in Google Scholar
  • 6 Fayssoil A, Nardi O, Orlikowski D, Annane D. Cardiomyopathy in Duchenne muscular dystrophy: pathogenesis and therapeutics. Heart Fail Rev 2010; 15 (01) 103-107
    CrossrefPubMedSearch in Google Scholar
  • 7 Matsumura T, Tamura T, Kuru S, Kikuchi Y, Kawai M. Carvedilol can prevent cardiac events in Duchenne muscular dystrophy. Intern Med 2010; 49 (14) 1357-1363
    CrossrefPubMedSearch in Google Scholar
  • 8 Duboc D, Meune C, Pierre B. et al. Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years' follow-up. Am Heart J 2007; 154 (03) 596-602
    CrossrefPubMedSearch in Google Scholar
  • 9 Araujo APQC, Nardes F, Fortes CPDD. et al. Brazilian consensus on Duchenne muscular dystrophy. Part 2: rehabilitation and systemic care. Arq Neuropsiquiatr 2018; 76 (07) 481-489
    CrossrefPubMedSearch in Google Scholar
  • 10 Jefferies JL, Eidem BW, Belmont JW. et al. Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy. Circulation 2005; 112 (18) 2799-2804
    CrossrefPubMedSearch in Google Scholar
  • 11 Nigro G, Comi LI, Politano L, Bain RJ. The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiol 1990; 26 (03) 271-277
    CrossrefPubMedSearch in Google Scholar
  • 12 Kaspar RW, Allen HD, Ray WC. et al. Analysis of dystrophin deletion mutations predicts age of cardiomyopathy onset in Becker muscular dystrophy. Circ Cardiovasc Genet 2009; 2 (06) 544-551
    CrossrefPubMedSearch in Google Scholar
  • 13 Magri F, Govoni A, D'Angelo MG. et al. Genotype and phenotype characterization in a large dystrophinopathic cohort with extended follow-up. J Neurol 2011; 258 (09) 1610-1623
    CrossrefPubMedSearch in Google Scholar
  • 14 Deburgrave N, Daoud F, Llense S. et al. Protein- and mRNA-based phenotype-genotype correlations in DMD/BMD with point mutations and molecular basis for BMD with nonsense and frameshift mutations in the DMD gene. Hum Mutat 2007; 28 (02) 183-195
    CrossrefPubMedSearch in Google Scholar
  • 15 Diegoli M, Grasso M, Favalli V. et al. Diagnostic work-up and risk stratification in X-linked dilated cardiomyopathies caused by dystrophin defects. J Am Coll Cardiol 2011; 58 (09) 925-934
    CrossrefPubMedSearch in Google Scholar
  • 16 Tandon A, Jefferies JL, Villa CR. et al. Dystrophin genotype-cardiac phenotype correlations in Duchenne and Becker muscular dystrophies using cardiac magnetic resonance imaging. Am J Cardiol 2015; 115 (07) 967-971
    CrossrefPubMedSearch in Google Scholar
  • 17 Kantor PF, Lougheed J, Dancea A. et al; Children's Heart Failure Study Group. Presentation, diagnosis, and medical management of heart failure in children: Canadian Cardiovascular Society guidelines. Can J Cardiol 2013; 29 (12) 1535-1552
    CrossrefPubMedSearch in Google Scholar
  • 18 Ryder S, Leadley RM, Armstrong N. et al. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review. Orphanet J Rare Dis 2017; 12 (01) 79
    CrossrefPubMedSearch in Google Scholar
  • 19 Pichavant C, Aartsma-Rus A, Clemens PR. et al. Current status of pharmaceutical and genetic therapeutic approaches to treat DMD. Mol Ther 2011; 19 (05) 830-840
    CrossrefPubMedSearch in Google Scholar
  • 20 Kirchmann C, Kececioglu D, Korinthenberg R, Dittrich S. Echocardiographic and electrocardiographic findings of cardiomyopathy in Duchenne and Becker-Kiener muscular dystrophies. Pediatr Cardiol 2005; 26 (01) 66-72
    CrossrefPubMedSearch in Google Scholar
  • 21 Greiner E, Breaux A, Kasten J. et al. Cardiac atrial pathology in Duchenne muscular dystrophy. Muscle Nerve 2024; 69 (05) 572-579
    CrossrefPubMedSearch in Google Scholar
  • 22 Nigro G, Politano L, Nigro V, Petretta VR, Comi LI. Mutation of dystrophin gene and cardiomyopathy. Neuromuscul Disord 1994; 4 (04) 371-379
    CrossrefPubMedSearch in Google Scholar
  • 23 Spurney C, Shimizu R, Morgenroth LP, Kolski H, Gordish-Dressman H, Clemens PR. CINRG Investigators. Cooperative International Neuromuscular Research Group Duchenne Natural History Study demonstrates insufficient diagnosis and treatment of cardiomyopathy in Duchenne muscular dystrophy. Muscle Nerve 2014; 50 (02) 250-256
    CrossrefPubMedSearch in Google Scholar
  • 24 Ashwath ML, Jacobs IB, Crowe CA, Ashwath RC, Super DM, Bahler RC. Left ventricular dysfunction in Duchenne muscular dystrophy and genotype. Am J Cardiol 2014; 114 (02) 284-289
    CrossrefPubMedSearch in Google Scholar
  • 25 Zhou H, Fu M, Mao B, Yuan L. Cardiac phenotype–genotype associations in DMD/BMD: a meta-analysis and systematic review. Pediatr Cardiol 2021; 42 (01) 189-198
    CrossrefPubMedSearch in Google Scholar